{"transactions":[{"id":942152,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:35:35.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001664928-26-000003","document":"wk-form4_1768008932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000166492826000003/wk-form4_1768008932.xml","form_type":"4"}},{"id":1029387,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T22:40:25.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period as follows: 25% of the options will vest on October 1, 2026, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":400000,"derivative":{"exercise_price":1.54,"expiration_date":"2025-09-30","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001664928-25-000008","document":"wk-form4_1759358422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000166492825000008/wk-form4_1759358422.xml","form_type":"4"}},{"id":1583494,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-11T17:15:36.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the \"Effective Time\"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the \"Common Stock Merger Consideration\" and each such Stock Option, an"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the \"Effective Time\"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the \"Common Stock Merger Consideration\" and each such Stock Option, an"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the \"Effective Time\"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the \"Common Stock Merger Consideration\" and each such Stock Option, an"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":11.3,"underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000950170-24-029425","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664928/000095017024029425/ownership.xml","form_type":"4"}},{"id":1699957,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T16:10:05.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the stock option shall vest and become exercisable on the first anniversary of December 21, 2023, and the remainder vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":11.3,"expiration_date":"2033-12-20","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000950170-23-073031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664928/000095017023073031/ownership.xml","form_type":"4"}},{"id":2126811,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-02T19:06:40.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the \"2022 Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date."}],"balance_after":95000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-10-30","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-22-055400","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664928/000120919122055400/doc4.xml","form_type":"4"}},{"id":2420839,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T17:06:22.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022."}],"balance_after":95000,"derivative":{"exercise_price":8.21,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-22-005630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664928/000120919122005630/doc4.xml","form_type":"4"}},{"id":3388589,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"2019 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388588,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the \"November 2018 Vesting Commencement Date\") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the November 2018 Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.24,"expiration_date":"2028-11-24","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388587,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the \"2018 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":13.55,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388586,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the \"December 2017 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":10.7,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388585,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the \"2017 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":20.4,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388584,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 18, 2016 (the \"2016 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20.17,"expiration_date":"2026-03-02","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388583,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"other","acquired":false,"shares":27677,"price":18,"value":498186.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"On September 16, 2019, the Reporting Person entered into a Tender and Support (the \"Support Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the \"Tender Offer\").  On October 22, 2019, Purchaser accepted the Tender Offer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388582,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-22","kind":"grant","acquired":true,"shares":15619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the \"RSU\"), of which 7,810 shares had vested and the remaining 15,619 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer.  The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 6)."}],"balance_after":27677,"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388581,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-10-24T19:10:50.000Z","date":"2019-10-11","kind":"grant","acquired":true,"shares":904,"price":9.2,"value":8316.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":12058,"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3388580,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-10-24T19:10:50.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":1345,"price":9.197,"value":12369.965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2019 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":11154,"source":{"system":"sec-edgar","filing":"0001209191-19-053921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053921/doc4.xml","form_type":"4"}},{"id":3548666,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-04-25T18:43:22.000Z","date":"2019-04-25","kind":"sale","acquired":false,"shares":1897,"price":13.8539,"value":26280.8483,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU.  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":9809,"source":{"system":"sec-edgar","filing":"0001209191-19-026033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119026033/doc4.xml","form_type":"4"}},{"id":3548665,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-04-25T18:43:22.000Z","date":"2019-04-23","kind":"grant","acquired":true,"shares":7810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the \"RSU\"). Up to 7,810 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the \"FDA\") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the \"FDA Filing Milestone\") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 7,810 shares subject to the RSU."}],"balance_after":11706,"source":{"system":"sec-edgar","filing":"0001209191-19-026033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119026033/doc4.xml","form_type":"4"}},{"id":3667997,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T16:43:46.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":135000,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-19-008565","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119008565/doc4.xml","form_type":"4"}},{"id":3667996,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2019-02-08T16:43:46.000Z","date":"2018-11-30","kind":"grant","acquired":true,"shares":273,"price":9.35,"value":2552.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2018 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":3896,"source":{"system":"sec-edgar","filing":"0001209191-19-008565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119008565/doc4.xml","form_type":"4"}},{"id":3751772,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-27T17:35:29.000Z","date":"2018-11-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the \"Vesting Commencement Date\") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":13.24,"expiration_date":"2028-11-24","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-060011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118060011/doc4.xml","form_type":"4"}},{"id":3751771,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Common Stock","published_at":"2018-11-27T17:35:29.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":2000,"price":9.35,"value":18700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":3623,"source":{"system":"sec-edgar","filing":"0001209191-18-060011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118060011/doc4.xml","form_type":"4"}},{"id":4044064,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-21T17:46:48.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":70000,"derivative":{"exercise_price":13.55,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-012055","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118012055/doc4.xml","form_type":"4"}},{"id":4128527,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-18T18:25:25.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":35000,"derivative":{"exercise_price":10.7,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-17-066205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117066205/doc4.xml","form_type":"4"}},{"id":4128526,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Common Stock","published_at":"2017-12-18T18:25:25.000Z","date":"2017-11-30","kind":"grant","acquired":true,"shares":1623,"price":9.35,"value":15175.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2017 in a transaction exempt under Rule 16b-3(c)."}],"balance_after":1623,"source":{"system":"sec-edgar","filing":"0001209191-17-066205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117066205/doc4.xml","form_type":"4"}},{"id":4475230,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T17:33:13.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":50000,"derivative":{"exercise_price":20.4,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-006441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117006441/doc4.xml","form_type":"4"}}]}